doi: 10.1111/j.1651-2227.1993.tb12626.x
Since its discovery, GLP-1 has emerged as an incretin hormone for its facilitation in insulin release and reduction of insulin resistance (IR)
It works by: Slowing how quickly food leaves your stomach Sending fullness signals to your brain sooner Reducing cravings and food noise Helping you feel satisfied with less food Rather than forcing appetite suppression, semaglutide reshapes hunger signals over time
More about this Pin Protein is a critical nutrient for health, offering a range of benefits
Additionally, GLP-1 RAs with established CV benefitsspecifically liraglutide, subcutaneous semaglutide, dulaglutide, and efpeglenatideare recommended for patients with T2DM and ASCVD to reduce CV events, regardless of baseline or target HbA1c levels or concurrent glucose-lowering therapy (Class I, LoE A)